Chalazion in a patient with multiple myeloma treated with bortezomib.

Abstract

We present a case of a woman in her early 60s with multiple myeloma who, while undergoing treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), noticed a whitish nodular swelling on the eyelid. This occurred after one cycle of CyBorD and on subsequent treatment, it also involved the contralateral eyelid. The lesions were initially managed with conservative measures by applying warm compresses, but the lesions progressively increased in size. CyBorD was discontinued and topical antibiotics and anti-inflammatories were initiated, resulting in a decrease in size of the lesions. On resolution of symptoms, she was rechallenged with CyBorD, and symptoms did not recur. The temporal relationship between bortezomib and the development of chalazion is based on connection and no association has been proven.

• Authors: Bipin Ghimire, Yuko Hamajima, Lorena Carbajal-Carballo, Nwabundo Anusim
• Journal: BMJ case reports (BMJ Case Rep) Vol. 15 Issue 12 (Dec 07 2022) ISSN: 1757-790X [Electronic] England
• PMID: 36593601 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Bortezomib
• Dexamethasone
• Cyclophosphamide

Topics

• Female
• Humans
• Multiple Myeloma (drug therapy)
• Bortezomib (therapeutic use)
• Chalazion
• Dexamethasone (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols
• Retrospective Studies
• Neoplasm Recurrence, Local
• Cyclophosphamide (therapeutic use)